Key result
A novel non-steady-state kinetic model demonstrated basal apoB48 secretion of approximately 50 mg/day and an increment during fat absorption of about 230 mg/day into CM, VLDL1, and VLDL2.
Why the study?
Triglyceride-rich lipoproteins and their remnants are major cardiovascular risk factors, requiring new experimental approaches to simultaneously investigate the dynamics of chylomicrons, apoB48 metabolism, and VLDL apoB100.
A novel non-steady-state kinetic model provides new insights into human apoB48 metabolism, demonstrating direct intestinal release of apoB48 into VLDL particles and quantifying basal and postprandial secretion rates.
New mass spectrometric method enables simultaneous CM/VLDL apoB kinetics; leaves open clinical translation for TRL risk assessment.
Background Triglyceride‐rich lipoproteins and their remnants have emerged as major risk factors for cardiovascular disease. New experimental approaches are required that permit simultaneous investigation of the dynamics of chylomicrons ( CM ) and apoB48 metabolism and of apoB100 in very low‐density lipoproteins ( VLDL ). Methods Mass spectrometric techniques were used to determine the masses and tracer enrichments of apoB48 in the CM , VLDL 1 and VLDL 2 density intervals. An integrated non‐steady‐state multicompartmental model was constructed to describe the metabolism of apoB48‐ and apoB100‐containing lipoproteins following a fat‐rich meal, as well as during prolonged fasting. Results The kinetic model described the metabolism of apoB48 in CM , VLDL 1 and VLDL 2 . It predicted a low level of basal apoB48 secretion and, during fat absorption, an increment in apoB48 release into not only CM but also directly into VLDL 1 and VLDL 2 . ApoB48 particles with a long residence time were present in VLDL , and in subjects with high plasma triglycerides, these lipoproteins contributed to apoB48 measured during fasting conditions. Basal apoB48 secretion was about 50 mg day −1 , and the increment during absorption was about 230 mg day −1 . The fractional catabolic rates for apoB48 in VLDL 1 and VLDL 2 were substantially lower than for apoB48 in CM . Discussion This novel non‐steady‐state model integrates the metabolic properties of both apoB100 and apoB48 and the kinetics of triglyceride. The model is physiologically relevant and provides insight not only into apoB48 release in the basal and postabsorptive states but also into the contribution of the intestine to VLDL pool size and kinetics.
No takes yet. Share an insight, caveat, or question.
Björnson et al. (2019) studied this question. Fat-rich meal vs. Prolonged fasting was evaluated on ApoB48 metabolism and kinetics. A novel non-steady-state kinetic model demonstrated basal apoB48 secretion of approximately 50 mg/day and an increment during fat absorption of about 230 mg/day into CM, VLDL1, and VLDL2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: